vs
MESA LABORATORIES INC（MLAB）とRalliant Corp（RAL）の財務データ比較。上の社名をクリックして会社を切り替えられます
Ralliant Corpの直近四半期売上が大きい（$529.1M vs $65.1M、MESA LABORATORIES INCの約8.1倍）。Ralliant Corpの純利益率が高く（7.5% vs 5.6%、差は2.0%）。MESA LABORATORIES INCの前年同期比売上増加率が高い（3.6% vs -0.5%）。Ralliant Corpの直近四半期フリーキャッシュフローが多い（$126.6M vs $18.0M）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
MLAB vs RAL — 直接比較
売上が大きい
RAL
8.1倍大きい
$65.1M
売上成長率が高い
MLAB
+4.1%の差
-0.5%
純利益率が高い
RAL
純利益率が2.0%高い
5.6%
フリーキャッシュフローが多い
RAL
FCF $108.6M多い
$18.0M
損益計算書 — Q3 2026 vs Q3 2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $529.1M |
| 純利益 | $3.6M | $39.9M |
| 粗利率 | 64.2% | 50.8% |
| 営業利益率 | 12.2% | 9.8% |
| 純利益率 | 5.6% | 7.5% |
| 売上前年比 | 3.6% | -0.5% |
| 純利益前年比 | 316.6% | -56.1% |
| EPS（希薄化後） | $0.65 | $0.35 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上MLABRAL
| Q4 25 | $65.1M | — | ||
| Q3 25 | $60.7M | $529.1M | ||
| Q2 25 | $59.5M | $503.3M | ||
| Q1 25 | $62.1M | — | ||
| Q4 24 | $62.8M | — | ||
| Q3 24 | $57.8M | $531.7M | ||
| Q2 24 | $58.2M | $533.7M | ||
| Q1 24 | $58.9M | — |
純利益MLABRAL
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | $39.9M | ||
| Q2 25 | $4.7M | $47.6M | ||
| Q1 25 | $-7.1M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | $90.9M | ||
| Q2 24 | $3.4M | $64.8M | ||
| Q1 24 | $-254.6M | — |
粗利率MLABRAL
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | 50.8% | ||
| Q2 25 | 62.0% | 49.3% | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | 52.6% | ||
| Q2 24 | 64.0% | 51.5% | ||
| Q1 24 | 62.1% | — |
営業利益率MLABRAL
| Q4 25 | 12.2% | — | ||
| Q3 25 | 7.8% | 9.8% | ||
| Q2 25 | 5.1% | 11.7% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 6.1% | 20.9% | ||
| Q2 24 | 9.6% | 19.7% | ||
| Q1 24 | -460.6% | — |
純利益率MLABRAL
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | 7.5% | ||
| Q2 25 | 8.0% | 9.5% | ||
| Q1 25 | -11.4% | — | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | 17.1% | ||
| Q2 24 | 5.8% | 12.1% | ||
| Q1 24 | -432.2% | — |
EPS（希薄化後）MLABRAL
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.45 | $0.35 | ||
| Q2 25 | $0.85 | $0.42 | ||
| Q1 25 | $-1.30 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.63 | $0.81 | ||
| Q2 24 | $0.62 | $0.57 | ||
| Q1 24 | $-47.26 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $264.2M |
| 総負債低いほど良い | $68.4M | $1.1B |
| 株主資本純資産 | $186.7M | $3.0B |
| 総資産 | $434.8M | $5.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 0.39× |
8四半期トレンド — 暦四半期で整列
現金・短期投資MLABRAL
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | $264.2M | ||
| Q2 25 | $21.3M | $198.6M | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
総負債MLABRAL
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | $1.1B | ||
| Q2 25 | $70.3M | $1.1B | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
株主資本MLABRAL
| Q4 25 | $186.7M | — | ||
| Q3 25 | $178.5M | $3.0B | ||
| Q2 25 | $172.5M | $3.0B | ||
| Q1 25 | $159.8M | — | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $161.5M | $4.0B | ||
| Q2 24 | $150.7M | $4.0B | ||
| Q1 24 | $145.4M | — |
総資産MLABRAL
| Q4 25 | $434.8M | — | ||
| Q3 25 | $430.4M | $5.3B | ||
| Q2 25 | $435.7M | $5.2B | ||
| Q1 25 | $433.3M | — | ||
| Q4 24 | $433.3M | — | ||
| Q3 24 | $454.1M | — | ||
| Q2 24 | $440.4M | — | ||
| Q1 24 | $446.8M | — |
負債/資本比率MLABRAL
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | 0.39× | ||
| Q2 25 | 0.41× | 0.38× | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $138.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $126.6M |
| FCFマージンFCF / 売上 | 27.7% | 23.9% |
| 設備投資強度設備投資 / 売上 | 1.1% | 2.3% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 3.47× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローMLABRAL
| Q4 25 | $18.8M | — | ||
| Q3 25 | $8.2M | $138.6M | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $12.7M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $12.9M | — |
フリーキャッシュフローMLABRAL
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | $126.6M | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
FCFマージンMLABRAL
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | 23.9% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
設備投資強度MLABRAL
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | 2.3% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
キャッシュ転換率MLABRAL
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | 3.47× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
